Changing outcome in inflammatory neuropathies Rasch-comparative responsiveness

Neurology

Volumn 83, Issue 23, 2014, Pages 2124-2132

  Draak, Thomas H P ^a   Vanhoutte, Els K ^a   Van Nes, Sonja I ^b   Gorson, Kenneth C ^m   Van Der Pol, W Ludo ⁿ   Notermans, Nicolette C ^c   Nobile Orazio, Eduardo ^d   Léger, Jean Marc ^e   Van Den Bergh, Peter Y K ^c,e   Lauria, Giuseppe ^f   Bril, Vera ^g   Katzberg, Hans ^g   Lunn, Michael P T ^h   Pouget, Jean ⁱ   Van Der Kooi, Anneke J ^j   Hahn, Angelika F ^k   Van Doorn, Pieter A ^b   Cornblath, David R ^l   Van Den Berg, Leonard H ^c   Faber, Catharina G ^a   Merkies, Ingemar S J ^a,o   more..

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF MILAN   (Italy)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^h Neurology Unit   (Italy)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

^j NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^k TIMONE HOSPITAL   (France)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

^m LONDON HEALTH SCIENCES CENTRE   (Canada)

ⁿ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o Infection and Immunology   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DISABILITY; DISEASE ACTIVITY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; INFLAMMATORY NEUROPATHY CAUSE AND TREATMENT OVERALL NEUROPATHY LIMITATION SCALE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASCH ANALYSIS; RATING SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; POLYNEUROPATHIES; POLYRADICULONEUROPATHY; SEVERITY OF ILLNESS INDEX; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; POLYNEUROPATHIES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84925284128     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001044     Document Type: Article

References (40)

1. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): A randomised placebo-controlled trial. Lancet Neurol 2008;7:136-144.
2. Dalakas MC, Rakocevic G, Salajegheh M, et al. Place bocontrolled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65:286-293.
3. van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-196.
4. Leger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 2013;80:2217-2225.
5. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: A randomised controlled trial. Lancet Neurol 2012;11:493-502.
6. van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT Study): A double-blind, randomised, controlled trial. Lancet Neurol 2010;9:245- 253.
7. DeVellis RF. Classical test theory. Med Care 2006;44: S50-S59.
8. Merkies IS, Lauria G, Faber CG. Outcome measures in peripheral neuropathies: requirements through statements. Curr Opin Neurol 2012;25:556-563.
9. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
10. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006;77:973-976.
11. van Nes SI, Vanhoutte EK, van Doorn PA, et al. Raschbuilt Overall Disability Scale (R-ODS) for immunemediated peripheral neuropathies. Neurology 2011;76: 337-345.
12. Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001;45:133-139.
13. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 2010;15:1-9.
14. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 2010;15:185-195.
15. Rasch G. Probabilistic Models for Some Intelligence and Attainment Tests. Chicago: University of Chicago Press; 1960.
16. Tennant A, Conaghan PG. The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis Rheum 2007;57:1358-1362.
17. Wright BD, Linacre JM. Observations are always ordinal; measurements, however, must be interval. Arch Phys Med Rehabil 1989;70:857-860.
18. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596-601.
19. Hermans MC, Faber CG, De Baets MH, de Die- Smulders CE, Merkies IS. Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ). Neuromuscul Disord 2010;20:310-318.
20. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 2009;13:iii, ix-x, 1-177.
21. Vanhoutte EK, Faber CG, Merkies IS. 196th ENMC International Workshop: outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, the Netherlands. Neuromuscul Disord 2013;23:924-933.
22. Heesch KC, Masse LC, Dunn AL. Using Rasch modeling to re-evaluate three scales related to physical activity: enjoyment, perceived benefits and perceived barriers. Health Educ Res 2006(21 suppl 1):i58-i72.
23. Liang MH. Evaluating measurement responsiveness. J Rheumatol 1995;22:1191-1192.
24. van Nes SI, Faber CG, Merkies IS. Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst 2008;13:136-147.
25. EuroQol Group. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199-208.
26. van der Beek NA, Hagemans ML, van der Ploeg AT, van Doorn PA, Merkies IS. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord 2013;23:256-264.
27. Herndon JE II, Harrell FE Jr. The restricted cubic spline hazard model. Comm Stat Theory Meth 1990;19:639-663.
28. Kucukdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum 2004;51:14-19.
29. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417-1432.
30. Andrich D. Relationships between the Thurstone and Rasch approaches to item scaling. Appl Psychol Meas 1978;2:449-460.
31. Andrich D, Sheridan B, Luo G. Rasch Models for Measurement: RUMM2030. Perth: RUMM Laboratory; 2010.
32. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2012;5:CD002827.
33. Knutsson I, Rydstrom H, Reimer J, Nyberg P, Hagell P. Interpretation of response categories in patient-reported rating scales: A controlled study among people with Parkinson's disease. Health Qual Life Outcomes 2010;8:61.
34. Stucki G, Daltroy L, Katz JN, Johannesson M, Liang MH. Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol 1996;49:711-717.
35. Vanhoutte EK, Faber CG, van Nes SI, et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 2012;135:1639-1649.
36. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007;6:1094-1105.
37. Grimby G, Tennant A, Tesio L. The use of raw scores from ordinal scales: time to end malpractice? J Rehabil Med 2012;44:97-98.
38. Merbitz C, Morris J, Grip JC. Ordinal scales and foundations of misinference. Arch Phys Med Rehabil 1989;70: 308-312.
39. Stevens SS. On the theory of scales of measurement. Science 1946;103:677-680.
40. Tubach F, Dougados M, Falissard B, Baron G, Logeart I, Ravaud P. Feeling good rather than feeling better matters more to patients. Arthrit Rheum 2006;55:526-530.